Holen Sie sich die Stockscreener-App
1.44
2.86%
0.04
Handel nachbörslich:
1.44
Schlusskurs vom Vortag:
$1.40
Offen:
$1.43
24-Stunden-Volumen:
1.34M
Relative Volume:
0.28
Marktkapitalisierung:
$449.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-5.3333
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
+2.13%
1M Leistung:
+21.01%
6M Leistung:
+39.13%
1J Leistung:
+100.50%
1-Tages-Spanne:
$1.41
$1.465
1-Wochen-Bereich:
$1.365
$1.58
52-Wochen-Spanne:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.44 | 437.25M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Shares Navigate Year-End Consolidation Phase - AD HOC NEWS
Ocugen’s Pipeline Progress: Targeting Unmet Needs in Rare Eye Diseases - AD HOC NEWS
Is Ocugen’s (OCGN) Rare Disease Summit Spotlight Reframing Its Gene Therapy Investment Narrative? - Yahoo Finance
Is Ocugen (OCGN) Quietly Reframing Its Risk Profile Around Rare Disease Gene Therapies? - simplywall.st
Why Ocugen Inc. stock is a must watch in 2025Energy Sector Updates & Achieve Triple Digit Returns - Bollywood Helpline
Why Ocugen Inc. (2H51) stock stays on top picksOptions Play & Community Verified Trade Signals - Улправда
Can Ocugen Inc. stock weather global recession2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Bear Alert: Can Ocugen Inc. stock weather global recessionJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Ocugen Inc. stock deliver strong dividend growth2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
Ocugen Ties CEO Compensation to Regulatory and Stock Performance - AD HOC NEWS
Is Ocugen Inc. (2H51) stock dividend growth reliable2025 Trading Volume Trends & Technical Entry and Exit Tips - DonanımHaber
Why Ocugen Inc. (2H51) stock is listed among top recommendationsMarket Performance Summary & Weekly Consistent Profit Watchlists - DonanımHaber
Will Ocugen Inc. stock maintain growth story2025 Risk Factors & Low Drawdown Trading Strategies - DonanımHaber
Ocugen Grants CEO New Performance-Based Equity Award - TipRanks
Pharma News: Why Ocugen Inc. stock is a must watch in 2025July 2025 Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Why pension funds invest in Ocugen Inc. (2H51) stockAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Ocugen Shares Face Mounting Pressure Amid Financial Concerns - AD HOC NEWS
Ocugen Inc. Stock Rises Tuesday, Outperforms Market - 富途牛牛
Ocugen Inc. Stock Rises Monday, Outperforms Market - 富途牛牛
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - Nasdaq
Ocugen (NASDAQ:OCGN) Shares Up 1.5%What's Next? - MarketBeat
How The Latest Analyst Shifts Are Reshaping Ocugen’s Story and Valuation - Yahoo Finance
Ocugen Inc Stock Analysis and ForecastSector Rotation Strategies & Free Rapid Growing Investment Returns - earlytimes.in
Growth Recap: Is Ocugen Inc stock supported by strong cash flowsJuly 2025 Review & Stepwise Trade Execution Plans - moha.gov.vn
Institutional Giant Janus Henderson Makes Major Bet on Ocugen - AD HOC NEWS
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Ocugen I - GuruFocus
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen CEO’s Keynote Address Meets Heightened Market Skepticism - Ad-hoc-news.de
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen, Inc. Chairman and CEO Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit - Quiver Quantitative
Major Fund Manager Acquires Significant Stake in Ocugen Amid Share Price Weakness - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. Stock Falls Friday, Underperforms Market - 富途牛牛
Institutional Backing and Geopolitical Tailwinds for Ocugen - AD HOC NEWS
Ocugen Secures Validating Partnership for Gene Therapy Platform - AD HOC NEWS
How robust is Ocugen Inc. (2H51) stock financial positionMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
Why institutional investors increase stakes in Ocugen Inc. (2H51) stockJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
How Ocugen Inc. (2H51) stock compares with tech leadersEarnings Growth Summary & Weekly Hot Stock Watchlists - Newser
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Is Ocugen Inc. (2H51) stock resilient in recession scenarios2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
Why Ocugen Inc. stock appeals to analystsWeekly Trade Analysis & Risk Controlled Swing Alerts - Newser
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference - MSN
Can Ocugen Inc. (2H51) stock deliver consistent EPS growth2025 Volatility Report & Safe Capital Growth Stock Tips - Newser
Is Ocugen Inc. (2H51) stock good for long term investingRisk Management & Free Community Consensus Stock Picks - Newser
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments - Yahoo Finance
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MSN
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):